Additionally, several immune checkpoint signals, including PD‐1/PD‐L1, TIM3/Gal9 and TIGIT/PVR, were upregulated in these two patients, indicating adaptive immune resistance occurred in these two patients, which suggested that immune checkpoint inhibitors might be an effective therapeutic strategy for certain SCCE individuals. This evidence concerns the gene PVR and cervical small cell carcinoma.